PAVmed Inc (PAVMZ) is a publicly traded company in the Healthcare sector, operating within the Medical - Devices industry. The company is headquartered in New York City, DE, United States. The current CEO is Lishan Aklog.
PAVMZ has IPO date of 2018-04-10, 39 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $11.92K.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
